Quarterly report pursuant to Section 13 or 15(d)

Revenue Recognition - Schedule of Revenue by Service Line (Details)

v3.24.3
Revenue Recognition - Schedule of Revenue by Service Line (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Disaggregation of Revenue [Line Items]        
Total revenue $ 8,122 $ 5,762 $ 23,619 $ 17,145
Biologics and drug delivery        
Disaggregation of Revenue [Line Items]        
Total revenue 4,431 3,487 13,065 9,531
Biologics and Drug Delivery - Disposable Products        
Disaggregation of Revenue [Line Items]        
Total revenue 2,062 455 4,286 1,395
Biologics and Drug Delivery - Services and license fees        
Disaggregation of Revenue [Line Items]        
Total revenue 2,369 3,032 8,779 8,136
Neurosurgery navigation and therapy        
Disaggregation of Revenue [Line Items]        
Total revenue 2,860 1,918 7,373 6,480
Neurosurgery Navigation and Therapy - Disposable Products        
Disaggregation of Revenue [Line Items]        
Total revenue 2,860 1,874 7,373 5,550
Neurosurgery Navigation and Therapy - Services        
Disaggregation of Revenue [Line Items]        
Total revenue 0 44 0 930
Capital equipment and software        
Disaggregation of Revenue [Line Items]        
Total revenue 831 357 3,181 1,134
Capital Equipment and Software - Systems and Software Products        
Disaggregation of Revenue [Line Items]        
Total revenue 552 81 2,394 432
Capital Equipment and Software - Services        
Disaggregation of Revenue [Line Items]        
Total revenue $ 279 $ 276 $ 787 $ 702